MMEDF - MindMed Announces Launch of Collaboration with Nextage Therapeutics' Brain Targeting Liposome System

NEW YORK, May 24, 2021 /CNW/ — Mind Medicine (MindMed) Inc. (NEO: MMED)(OTC:MMEDF)(DE: BGHM), a leading clinical-stage psychedelic medicine company, and Nextage Therapeutics (TASE: NXTG), an Israeli innovative drug development company, announced the execution of a Memorandum of Understanding (the “MOU”) regarding the launch of an exclusive collaborative development program to optimize the delivery of certain psychedelic drug candidates, leveraging Nextage’s proprietary Brain Targeting Liposome System (BTLS) delivery technology, for which it has an exclusive license.  MindMed and Nextage will initially collaborate to optimize the delivery of drug products based on noribogaine, and ultimately other ibogaine derivatives, and will ...